{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:49:59Z","timestamp":1787593799102,"version":"build-2736575974"},"reference-count":45,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Regenerative Medicine Minnesota","award":["P008848103"],"award-info":[{"award-number":["P008848103"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>GDP-mannose pyrophosphorylase B (GMPPB) is a cytoplasmic protein that catalyzes the formation of GDP-mannose. Impaired GMPPB function reduces the amount of GDP-mannose available for the O-mannosylation of \u03b1-dystroglycan (\u03b1-DG) and ultimately leads to disruptions of the link between \u03b1-DG and extracellular proteins, hence dystroglycanopathy. GMPPB-related disorders are inherited in an autosomal recessive manner and caused by mutations in either a homozygous or compound heterozygous state. The clinical spectrum of GMPPB-related disorders spans from severe congenital muscular dystrophy (CMD) with brain and eye abnormalities to mild forms of limb-girdle muscular dystrophy (LGMD) to recurrent rhabdomyolysis without overt muscle weakness. GMPPB mutations can also lead to the defect of neuromuscular transmission and congenital myasthenic syndrome due to altered glycosylation of the acetylcholine receptor subunits and other synaptic proteins. Such impairment of neuromuscular transmission is a unique feature of GMPPB-related disorders among dystroglycanopathies. LGMD is the most common phenotypic presentation, characterized by predominant proximal weakness involving lower more than upper limbs. Facial, ocular, bulbar, and respiratory muscles are largely spared. Some patients demonstrate fluctuating fatigable weakness suggesting neuromuscular junction involvement. Patients with CMD phenotype often also have structural brain defects, intellectual disability, epilepsy, and ophthalmic abnormalities. Creatine kinase levels are typically elevated, ranging from 2 to &gt;50 times the upper limit of normal. Involvement of the neuromuscular junction is demonstrated by the decrement in the compound muscle action potential amplitude on low-frequency (2\u20133 Hz) repetitive nerve stimulation in proximal muscles but not in facial muscles. Muscle biopsies typically show myopathic changes with variable degrees of reduced \u03b1-DG expression. Higher mobility of \u03b2-DG on Western blotting represents a specific feature of GMPPB-related disorders, distinguishing it from other \u03b1-dystroglycanopathies. Patients with clinical and electrophysiologic features of neuromuscular transmission defect can respond to acetylcholinesterase inhibitors alone or combined with 3,4 diaminopyridine or salbutamol.<\/jats:p>","DOI":"10.3390\/genes14020372","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T03:22:47Z","timestamp":1675221767000},"page":"372","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["GDP-Mannose Pyrophosphorylase B (GMPPB)-Related Disorders"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9682-2372","authenticated-orcid":false,"given":"Pitcha","family":"Chompoopong","sequence":"first","affiliation":[{"name":"Department of Neurology, Division of Neuromuscular Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4338-9007","authenticated-orcid":false,"given":"Margherita","family":"Milone","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Neuromuscular Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Kanagawa, M. (2021). Dystroglycanopathy: From Elucidation of Molecular and Pathological Mechanisms to Development of Treatment Methods. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222313162"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJMoa1006939","article-title":"A Dystroglycan Mutation Associated with Limb-Girdle Muscular Dystrophy","volume":"364","author":"Hara","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","article-title":"Muscular dystrophies","volume":"394","author":"Mercuri","year":"2019","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0140-6736(02)11397-3","article-title":"Defective glycosylation in muscular dystrophy","volume":"360","author":"Muntoni","year":"2002","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1126\/science.1180512","article-title":"O-Mannosyl Phosphorylation of Alpha-Dystroglycan Is Required for Laminin Binding","volume":"327","author":"Yu","year":"2010","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ajhg.2013.05.009","article-title":"Mutations in GDP-Mannose Pyrophosphorylase B Cause Congenital and Limb-Girdle Muscular Dystrophies Associated with Hypoglycosylation of \u03b1-Dystroglycan","volume":"93","author":"Carss","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/8904_2017_25","article-title":"Mutations in GMPPB Presenting with Pseudometabolic Myopathy","volume":"38","author":"Panicucci","year":"2018","journal-title":"JIMD Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/brain\/awv185","article-title":"Mutations in GMPPB cause congenital myasthenic syndrome and bridge my-asthenic disorders with dystroglycanopathies","volume":"138","author":"Belaya","year":"2015","journal-title":"Brain"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.nmd.2019.07.001","article-title":"A homozygous mutation in GMPPB leads to centronuclear myopathy with combined pre- and postsynaptic defects of neuromuscular transmission","volume":"29","author":"Nicolau","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/jnnp-2016-313163","article-title":"Clinical features of the myasthenic syndrome arising from mutations in GMPPB","volume":"87","author":"Cruz","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.bbagen.2008.03.005","article-title":"Dolichol-phosphate mannose synthase: Structure, function and regulation","volume":"1780","author":"Maeda","year":"2008","journal-title":"Biochim. Biophys. Acta-Gen. Subj."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature00837","article-title":"Post-translational disruption of dystroglycan\u2014Ligand interactions in congenital muscular dystrophies","volume":"418","author":"Michele","year":"2002","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.mam.2016.07.003","article-title":"Mechanistic aspects of the formation of \u03b1-dystroglycan and therapeutic re-search for the treatment of \u03b1-dystroglycanopathy: A review","volume":"51","author":"Morioka","year":"2016","journal-title":"Mol. Asp. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1086\/342975","article-title":"Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome","volume":"71","author":"Currier","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/jmg.2005.031963","article-title":"POMT2 mutations cause alpha-dystroglycan hypoglycosylation and Walker-Warburg syndrome","volume":"42","author":"Janssen","year":"2005","journal-title":"J. Med. Genet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1534-5807(01)00070-3","article-title":"Muscular Dystrophy and Neuronal Migration Disorder Caused by Mutations in a Glycosyltransferase, POMGnT1","volume":"1","author":"Yoshida","year":"2001","journal-title":"Dev. Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ana.23632","article-title":"DPM2-CDG: A muscular dystrophy-dystroglycanopathy syndrome with severe epilepsy","volume":"72","author":"Barone","year":"2012","journal-title":"Ann. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ajhg.2009.06.006","article-title":"Deficiency of Dol-P-Man Synthase Subunit DPM3 Bridges the Congenital Disorders of Glycosylation with the Dystroglycanopathies","volume":"85","author":"Lefeber","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lefeber, D.J., de Brouwer, A.P.M., Morava, E., Riemersma, M., Schuurs-Hoeijmakers, J.H.M., Absmanner, B., Verrijp, K., Akker, W.M.R.V.D., Huijben, K., and Steenbergen, G. (2011). Autosomal Recessive Dilated Cardiomyopathy due to DOLK Mutations Results from Abnormal Dystroglycan O-Mannosylation. PLoS Genet., 7.","DOI":"10.1371\/journal.pgen.1002427"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13023-018-0863-x","article-title":"Broad phenotypic spectrum and genotype-phenotype correlations in GMPPB-related dystroglycanopathies: An Italian cross-sectional study","volume":"13","author":"Astrea","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1136\/jnnp-2017-316956","article-title":"Mobility shift of beta-dystroglycan as a marker of GMPPB gene-related muscular dystrophy","volume":"89","author":"Sarkozy","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/humu.22898","article-title":"GMPPB-Associated Dystroglycanopathy: Emerging Common Variants with Phenotype Correlation","volume":"36","author":"Jensen","year":"2015","journal-title":"Hum. Mutat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00415-022-11440-0","article-title":"The clinical and molecular landscape of congenital myasthenic syndromes in Austria: A na-tionwide study","volume":"270","author":"Krenn","year":"2022","journal-title":"J. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/brain\/awv013","article-title":"Expanding the phenotype of GMPPB mutations","volume":"138","author":"Ghaoui","year":"2015","journal-title":"Brain"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1212\/NXG.0000000000000112","article-title":"Muscle involvement in limb-girdle muscular dystrophy with GMPPB deficiency (LGMD2T)","volume":"2","author":"Oestergaard","year":"2016","journal-title":"Neurol. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/mus.25485","article-title":"Two patients with GMPPB mutation: The overlapping phenotypes of limb-girdle myasthenic syndrome and limb-girdle muscular dystrophy dystroglycanopathy","volume":"56","author":"Montagnese","year":"2017","journal-title":"Muscle Nerve"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1212\/WNL.0000000000001440","article-title":"Intrafamilial variability in GMPPB-associated dystroglycanopathy: Broadening of the phenotype","volume":"84","author":"Neil","year":"2015","journal-title":"Neurology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.nmd.2017.04.006","article-title":"Late-onset limb-girdle muscular dystrophy caused by GMPPB mutations","volume":"27","author":"Balcin","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.nmd.2020.01.002","article-title":"Clinical and electrophysiological evaluation of myasthenic features in an alpha-dystroglycanopathy cohort (FKRP-predominant)","volume":"30","author":"Smith","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s43556-021-00027-2","article-title":"GMPPB-congenital disorders of glycosylation associate with decreased enzymatic activity of GMPPB","volume":"2","author":"Liu","year":"2021","journal-title":"Mol. Biomed."},{"key":"ref_31","first-page":"275","article-title":"Limb-girdle muscular dystrophy due to GMPPB mutations: A case report and comprehensive literature review","volume":"20","author":"Sun","year":"2020","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/cge.13886","article-title":"Genetic variations and clinical spectrum of dystroglycanopathy in a large cohort of Chinese patients","volume":"99","author":"Song","year":"2021","journal-title":"Clin. Genet."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.nmd.2018.07.001","article-title":"Steroid therapy in an alpha-dystroglycanopathy due to GMPPB gene mutations: A case report","volume":"28","author":"Fecarotta","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.nmd.2017.08.003","article-title":"Molecular characterization of congenital myasthenic syndromes in Spain","volume":"27","author":"Benito","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.nmd.2020.07.009","article-title":"Early and long-term effect of the treatment with pyri-dostigmine in patients with GMPPB-related congenital myasthenic syndrome","volume":"30","author":"Benito","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.brainres.2014.04.028","article-title":"Congenital muscular dystrophy and generalized epilepsy caused by GMPPB mutations","volume":"1575","author":"Raphael","year":"2014","journal-title":"Brain Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/acn3.787","article-title":"Lysosomal degradation of GMPPB is associated with limb-girdle muscular dystrophy type 2T","volume":"6","author":"Tian","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.nmd.2017.03.004","article-title":"Novel mutations in the C-terminal region of GMPPB causing limb-girdle muscular dystrophy overlapping with congenital myasthenic syndrome","volume":"27","author":"Luo","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10048-021-00658-1","article-title":"A founder mutation in the GMPPB gene [c.1000G > A (p.Asp334Asn)] causes a mild form of limb-girdle muscular dystrophy\/congenital myasthenic syndrome (LGMD\/CMS) in South Indian patients","volume":"22","author":"Polavarapu","year":"2021","journal-title":"Neurogenetics"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/acn3.51346","article-title":"Congenital myasthenic syndrome in China: Genetic and myopathological characterization","volume":"8","author":"Zhao","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1212\/WNL.0000000000001303","article-title":"Prevalence of congenital muscular dystrophy in Italy: A population study","volume":"84","author":"Graziano","year":"2015","journal-title":"Neurology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.nmd.2017.06.008","article-title":"Congenital muscular dystrophies in the UK population: Clinical and molecular spectrum of a large cohort diagnosed over a 12-year period","volume":"27","author":"Sframeli","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0169-328X(96)00256-2","article-title":"N-Glycosylation at the conserved sites ensures the expression of properly folded functional ACh receptors","volume":"45","author":"Gehle","year":"1997","journal-title":"Mol. Brain Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1093\/hmg\/ddr396","article-title":"A valid mouse model of AGRIN-associated congenital myasthenic syndrome","volume":"20","author":"Bogdanik","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1093\/brain\/awu160","article-title":"Agrin mutations lead to a congenital myasthenic syndrome with distal muscle weakness and atrophy","volume":"137","author":"Nicole","year":"2014","journal-title":"Brain"}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/14\/2\/372\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:19:36Z","timestamp":1760120376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/14\/2\/372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,31]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["genes14020372"],"URL":"https:\/\/doi.org\/10.3390\/genes14020372","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,31]]}}}